Phase IIB Abstract -FINAL A large body of evidence supports the idea that disruptions in the regularity of behavioral routines (or ?social rhythms?) can lead to the onset of mood symptoms and full-blown episodes via their impact on endogenous circadian rhythms and, conversely, that stable social routines protect against new mood episodes. Based on our conviction that monitoring, evaluating, and increasing the regularity of behavioral rhythms has broad applicability for improving mental health, we established HealthRhythms, Inc. (www.healthrhythms.com) with the goal of using mobile technology to enhance our capacity to monitor and treat such conditions, with a particular emphasis on mood disorders. Our product vision capitalizes on the ubiquity and intimacy of smartphones and their capacity to automatically and continuously sense parameters of behavior that represent key indicators of depressive symptomatology captured on a 24/7 basis in the user?s natural environment. It also capitalizes on the capacity of smartphones to deliver interventions that are easily accessible, can be delivered with optimal timing and, perhaps most important, are enormously scalable. Finally, smartphone technology gives us the capacity to bring empirically validated psychosocial interventions to the hundreds of thousands of depressed patients who otherwise would not be able to access such interventions and, thus, speed their recovery and prevent relapse. Under the auspices of our Phase II SBIR funding (R44MH113520-01-02), we have developed both such a monitoring product (Measure) and have developed and tested such a digital intervention platform (Cue). Analyses conducted to date indicate that Cue leads to significantly greater decreases in depressive symptomatology than monitoring alone via Measure. We now propose to: 1) upgrade to Cue and its accompanying clinician dashboard to be commercially marketable and 2) carry out the clinical trial necessary for FDA licensing of Cue 2.0 as a mobile device. Cue 2.0 will include enhanced designs, more in-depth psychoeducational material, and a fully automated engine for delivering behavior change suggestions to improve the regularity of users? social and behavioral routines. Building on the accomplishments of our Phase II funding, this SBIR Phase IIB proposal is focused on bringing Cue to market as a scientifically validated and profitable digital intervention for individuals with depression with or without co-occurring anxiety disorder.
The Specific Aims are:
Aim 1 : Develop and validate Cue 2.0 a fully automated digital intervention platform.
Aim 2 : Carry out all necessary steps to apply for FDA licensing of Cue 2.0.
HealthRhythms, Inc. is on a mission to become the world leader in tracking clinically meaningful behavioral rhythms in order to provide automated behavior change suggestions to patients around the globe. The work we propose in this SBIR Phase IIB application will enable HealthRhythms to further develop Cue, our smartphone-based intervention platform for depression, and carry out the work necessary to obtain FDA clearance for Cue as a medical device. This will enable us to bring a tested psychosocial treatment to the hundreds of thousands of depressed patients who otherwise would not be able to access such treatment and, thus, speed their recovery and prevent relapse.
